Annals of Oncology 10:403-411, 1999
© 1999 European Society for Medical Oncology
research-article |
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results*
Departments of Breast Medical Oncology and Medical Specialties, The University of Texas, M.D. Anderson Cancer Centre Houston, TX, USA
Departments of Breast Medical Oncology and Medical Specialties, The University of Texas, M.D. Anderson Cancer Centre Houston, TX, USA
Purpose: We and others have demonstrated the antineoplastic efficacy of paclitaxel as a single agent in metastatic breast cancer. We performed this phase I trial to evaluate the combination of paclitaxel with doxorubicin.
Patients and methods: Eligible patients had measurable or evaluable metastatic breast cancer for which this was the initial cytotoxic treatment. They may have received adjuvant chemotherapy with other drugs. The study had four parts. In part 1, the patients received paclitaxel by 24-hour infusion followed by doxorubicin by 48-hour infusion. The paclitaxel dose was to be escalated from a starting dose of 125 mg/m2, and the doxorubicin dose was to remain constant at 60 mg/m with treatment repeated every three weeks. The results of part 1 prompted part 2 which was a study of the reverse sequence. Part 3 was a formal study of pharmacology and has been reported (J Clin Oncol 14: 2713–21, 1996). In part 4, patients received doxorubicin 50 mg/m2 by bolus followed by paclitaxel 150 mg/m2 by 24-hour infusion for courses 1 and 2. In all subsequent courses doxorubicin was administered by 48-hour infusion. All patients in all four parts of the study had baseline cardiac scans. All patients received standard premedication for paclitaxel.
Results: Forty-eight patients were treated in all four parts of the study. In part 1 (10 patients), the maximum tolerated dose (MTD) was paclitaxel 125 mg/m2/24 hours followed by doxorubicin 48 mg/m2/48 hours as defined by dose-limiting mucositis and neutropenic fever which occurred at the starting dose. For part 2 (21 patients), the MTD was doxorubicin 60 mg/m2/48 hours followed by paclitaxel 160 mg/m2/24 hours. In part 4 (seven patients), the MTD was doxorubicin 50 mg/m2/bolus followed by paclitaxel 135 mg/m2/24 hours. In parts 2 and 4, the dose-limiting toxic effect was neutropenia. Of the entire cohort of 48 patients, seven (15%) had a complete response (one persists at five years without intervening therapy), 26 (54%) had a partial response for an objective response rate of 69% (95% confidence interval (95% CI): 54%-81%). The median follow-up of all living patients is 38+ months (range 20+ to 62+); the median response duration is seven months (range 2-33.7+); the median overall survival is 20.5 months (range 5-54+). The median time to progression is 9.6 months (range 1-33.7+ months). Two patients developed congestive heart failure, one at 24 months after her final dose of doxorubicin which amounted to a cumulative lifetime total doxorubicin dose of 870 mg/m2, one after a total of 660 mg/m2. In both, cardiac symptoms were controlled with medications.
Conclusions: The combination of paclitaxel/24 hours with doxorubicin/48 hours is an effective antineoplastic treatment for metastatic breast cancer. However, the incidence of complete response, the median overall survival, and time to progression were not greater than for standard doxorubicin-based combinations. Additionally, a sequence-dependent interaction between paclitaxel and doxorubicin, given in the schedule described here, was defined. Other strategies and schedules should be evaluated to maximize the antineoplastic efficacy of these two potent agents.
breast cancer, doxorubicin, paclitaxel-anthracy-cline combination, schedule
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. R.J. H. Bird and S. M. Swain Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems Clin. Cancer Res., January 1, 2008; 14(1): 14 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Anelli, R. R. Brentani, A. P. Gadelha, A. Amorim de Albuquerque, and F. Soares Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer Ann. Onc., March 1, 2003; 14(3): 428 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lunardi, M. Venturini, M. O. Vannozzi, G. Tolino, L. Del Mastro, C. Bighin, G. Schettini, and M. Esposito Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer Ann. Onc., February 20, 2002; 13(2): 280 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-J. Tai, W.-S. Wang, J.-H. Liu, C.-C. Yen, F. S. Fan, T.-J. Chiou, and P.-M. Chen Salvage Therapy with Single-agent Paclitaxel by Three-hour Infusion in Metastatic Breast Cancer: an Experience in Taipei Veterans General Hospital Jpn. J. Clin. Oncol., October 1, 2001; 31(10): 477 - 481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Grasselli, L. Vigano, G. Capri, A. Locatelli, E. Tarenzi, C. Spreafico, A. Bertuzzi, A. Giani, C. Materazzo, S. Cresta, et al. Clinical and Pharmacologic Study of the Epirubicin and Paclitaxel Combination in Women With Metastatic Breast Cancer J. Clin. Oncol., April 15, 2001; 19(8): 2222 - 2231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Venturini, G. Lunardi, L. Del Mastro, M. O. Vannozzi, G. Tolino, G. Numico, M. Viale, I. Pastrone, C. Angiolini, G. Bertelli, et al. Sequence Effect of Epirubicin and Paclitaxel Treatment on Pharmacokinetics and Toxicity J. Clin. Oncol., May 10, 2000; 18(10): 2116 - 2125. [Abstract] [Full Text] [PDF]
|
|